BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
Shares of BioAffinity Technologies are surging Thursday after securing a key Hong Kong patent for its CyPath Lung diagnostic.
Stocks · News reference
bioAffinity Technologies shares are trading higher after the company announced that the Hong Kong Intellectual Property Department has granted a patent for the proprietary platform technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers to characterize cell populations in sputum.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Hong Kong Intellectual Property Department Grants Patent For bioAffinity’s Proprietary Platform Technology For Predicting Likelihood Of Lung Cancer Using Flow Cytometry And Fluorescent Markers To Characterize Cell Populations In Sputum
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian marketAsia accounts for nearly two-thirds of lung cancer cases worldwidebioAffinity Technologies, Inc. (NASDAQ:BIAF,
bioAffinity Technologies shares are trading higher after the company announced it regained compliance with the Nasdaq.